A single-dose phase I study of MepiGel in healthy volunteers

Trial Profile

A single-dose phase I study of MepiGel in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2015

At a glance

  • Drugs Mepivacaine (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2015 New trial record
    • 04 Feb 2015 Relmada Therapeutics plans to initiate this study with the selected MepiGel formulations later this year. The data from these studies will inform the design of a subsequent Phase 2 proof of concept study in patients suffering from neuropathic pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top